Manohursingh Runglall

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

Journal: Haematologica
Published: April 21, 2026

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Journal: Blood advances
Published: May 23, 2025

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Journal: Blood
Published: April 18, 2025

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Journal: The Lancet. Haematology
Published: May 01, 2024

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Journal: Blood
Published: February 27, 2024

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Journal: Blood
Published: November 03, 2023

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.

Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.

Journal: Blood
Published: April 04, 2022

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

Journal: Blood advances
Published: August 11, 2020

Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy.

Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy.

Journal: EBioMedicine
Published: May 16, 2020

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.

Journal: British journal of haematology
Published: February 26, 2020

Molecular MRD status and outcome after transplantation in NPM1-mutated AML.

Molecular MRD status and outcome after transplantation in NPM1-mutated AML.

Journal: Blood
Published: August 29, 2019

Gene expression biomarkers for kidney transplant rejection-The entire landscape-Author's reply.

Gene expression biomarkers for kidney transplant rejection-The entire landscape-Author's reply.

Journal: EBioMedicine
Published: March 20, 2019
Showing 1-12 of 21

Last Updated: 09/26/2026